ReviewDrugs in context2019
New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance.
Review in Drugs in context, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 142 citations in OpenAlex.
- Electroacupuncture alleviates intestinal inflammation in rats with ulcerative colitis by regulating colonic cell autophagy and gut microbiota.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Article
- Exploring the Treatment of Cinnamomum Cassia Leaf Extract in Ulcerative Colitis: Network Pharmacology and In Vitro Investigations.Plants (Basel, Switzerland) · 2026Article
- Inflammatory Bowel Disease Outcomes in Northern Iran: A Retrospective Cohort Study of Remission, Complications, and Treatment Strategies.BioMed research international · 2026Article
- Nanoencapsulated Syzygium aromaticum oil alleviates acetic acid-induced ulcerative colitis in rats by influencing critical redox, NF-κB/iNOS, and Keap1/Nrf2/HO-1 signaling pathways.Inflammopharmacology · 2025Article
- Therapeutic potential of alpha-lipoic acid on mitochondrial dynamics, oxidative/nitrosative stress, and histopathological changes in rat ulcerative colitis model.Inflammopharmacology · 2025Article
- Gemifloxacin ameliorates acetic acid-induced ulcerative colitis via modulation of inflammatory, oxidative, and adhesive biomarkers and histopathological changes in rats.Journal of molecular histology · 2025Article
- Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study.Inflammatory bowel diseases · 2025Article
- Suramin Exerts an Ameliorative Effect on Acetic Acid-Induced Acute Colitis in Rats by Demonstrating Potent Antioxidant and Anti-Inflammatory Properties.Medicina (Kaunas, Lithuania) · 2025Article
- Residual Disease Burden Among European Patients With Inflammatory Bowel Disease: A Real-World Survey.Inflammatory bowel diseases · 2025Observational
- The Analysis and Comparison of Anti-Inflammatory and Antioxidant Characteristics of Postbiotic and Paraprobiotic Derived From Novel Native Probiotic Cocktail in DSS-Induced Colitic Mice.Food science & nutrition · 2025Article
- Evaluating the Therapeutic Efficacy ofCurrent pharmaceutical design · 2025Review
- DJ-X-013 reduces LPS-induced inflammation, modulates Th17/ myeloid-derived suppressor cells, and alters NF-κB expression to ameliorate experimental colitis.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Article
- Therapeutic potential ofHeliyon · 2024Article
- Ginsenoside Rb1 Alleviates DSS-Induced Ulcerative Colitis by Protecting the Intestinal Barrier Through the Signal Network of VDR, PPARγ and NF-κB.Drug design, development and therapy · 2024Article
- 7-Dehydrocholesterol protects against circadian disruption and experimental colitis: potential role of RORα/γ.Life metabolism · 2023Article
- Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis.Digestive diseases and sciences · 2023Article
- Side Streams of Vegetable Processing and Its Bioactive Compounds Support Microbiota, Intestine Milieu, and Immune System.Molecules (Basel, Switzerland) · 2023Review
- Intestinal complications in Brazilian patients with ulcerative colitis treated with conventional therapy between 2011 and 2020.World journal of gastroenterology · 2023Observational
- New insights into the mechanisms of high-fat diet mediated gut microbiota in chronic diseases.iMeta · 2023Review
- Kimchi andFoods (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic idiopathic inflammatory disorder that involves any part of the colon starting in the rectum in a continuous fashion presenting typically with symptoms such as bloody diarrhea, abdominal pain, and rectal urgency. UC is diagnosed based on clinical presentation and endoscopic evidence of inflammation in the colon starting in the rectum and extending proximally in the colon. The clinical presentation of the disease usually dictates the choice of pharmacologic therapy, where the goal is to first induce remission and then maintain a corticosteroid-free remission. There are multiple classes of drugs that are available and are used based on the clinical severity of the disease. For mild-to-moderate disease, oral or rectal formulations of 5-aminosalicylic acid are used. In moderate-to-severe UC, corticosteroids are usually used in induction of remission with or without another class of medications such as thiopurines or biologics including anti-tumor necrosis factor, anti-integrins, or Janus kinase inhibitors for maintenance of remission. Up to 15% of the patients may require surgery as they fail to respond to medications and have risk of developing dysplasia secondary to longstanding colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.